• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Assessment of Tedizolid Activity and Resistance Mechanisms against a Collection of spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018.评估 Tedizolid 对引起侵袭性感染的 spp. 的活性和耐药机制，包括美国和欧洲医疗中心需要优化达托霉素给药策略的分离株，时间为 2016 年至 2018 年。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00175-20.
2
Effect of tedizolid on clinical Enterococcus isolates: in vitro activity, distribution of virulence factor, resistance genes and multilocus sequence typing.替加环素对临床分离肠球菌的影响：体外活性、毒力因子分布、耐药基因及多位点序列分型
FEMS Microbiol Lett. 2018 Feb 1;365(3). doi: 10.1093/femsle/fnx284.
3
A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin.一种赋予对恶唑烷酮类和酚类药物可转移抗性的新基因optrA，以及它在人和动物源粪肠球菌和屎肠球菌中的存在情况。
J Antimicrob Chemother. 2015 Aug;70(8):2182-90. doi: 10.1093/jac/dkv116. Epub 2015 May 14.
4
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.评价替加环素对金黄色葡萄球菌和对万古霉素、达托霉素或利奈唑胺敏感性降低的肠球菌的抗菌活性。
J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302. Epub 2015 Oct 16.
5
Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program.在全球范围内肠球菌临床分离株中不断演变的恶唑烷酮类耐药机制：来自 SENTRY 抗菌药物监测计划的结果。
J Antimicrob Chemother. 2018 Sep 1;73(9):2314-2322. doi: 10.1093/jac/dky188.
6
Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).韩国临床分离株中莫匹罗星、达托霉素、利奈唑胺、奎奴普丁/达福普汀和替加环素对耐万古霉素肠球菌（VRE）的抗菌活性（1998年和2005年）
J Biochem Mol Biol. 2007 Nov 30;40(6):881-7. doi: 10.5483/bmbrep.2007.40.6.881.
7
Interregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes.西班牙耐林可霉素肠球菌属分离株中携带 optrA 和 poxtA 基因的区际传播。
Int J Antimicrob Agents. 2020 Jun;55(6):105977. doi: 10.1016/j.ijantimicag.2020.105977. Epub 2020 Apr 22.
8
Detection of transferable oxazolidinone resistance determinants in Enterococcus faecalis and Enterococcus faecium of swine origin in Sichuan Province, China.中国四川省猪源粪肠球菌和屎肠球菌中可转移的恶唑烷酮类耐药决定因子的检测。
J Glob Antimicrob Resist. 2019 Dec;19:333-337. doi: 10.1016/j.jgar.2019.05.021. Epub 2019 May 25.
9
Typing of Enterococcus spp. strains in 4 hospitals in the Małopolska region in Poland.波兰小波兰省地区4家医院中肠球菌属菌株的分型
Adv Clin Exp Med. 2018 Jan;27(1):111-117. doi: 10.17219/acem/68265.
10
Efficacy of Tedizolid against Enterococci and Staphylococci, Including Strains, in a Mouse Peritonitis Model.替加环素对包括耐万古霉素肠球菌和金黄色葡萄球菌在内的肠球菌和葡萄球菌的疗效：一项在小鼠腹膜炎模型中的研究。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02627-18. Print 2019 Apr.

引用本文的文献

1
Linezolid in the Focus of Antimicrobial Resistance of Species: A Global Overview of Genomic Studies.利奈唑胺在细菌耐药性研究中的焦点：基因组研究的全球概述
Int J Mol Sci. 2025 Aug 24;26(17):8207. doi: 10.3390/ijms26178207.
2
Risk exploration and prediction model construction for linezolid-resistant Enterococcus faecalis based on big data in a province in southern China.基于中国南方某省大数据的耐利奈唑胺粪肠球菌风险探索与预测模型构建
Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):259-268. doi: 10.1007/s10096-023-04717-3. Epub 2023 Nov 30.
3
Five-year analysis of the activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme.针对全球范围内引起临床感染的目标菌种，对特地唑胺活性进行的五年分析：来自特地唑胺活性与耐药性监测（STAR）项目的结果
JAC Antimicrob Resist. 2022 Sep 5;4(5):dlac088. doi: 10.1093/jacamr/dlac088. eCollection 2022 Oct.
4
Pharmacokinetics and Pharmacodynamics of Tedizolid.替加环素的药代动力学和药效学。
Clin Pharmacokinet. 2022 Apr;61(4):489-503. doi: 10.1007/s40262-021-01099-7. Epub 2022 Feb 7.
5
Comparison of Anti-Microbic and Anti-Biofilm Activity Among Tedizolid and Radezolid Against Linezolid-Resistant Isolates.替地唑胺和瑞地唑胺对耐利奈唑胺菌株的抗微生物和抗生物膜活性比较
Infect Drug Resist. 2021 Nov 5;14:4619-4627. doi: 10.2147/IDR.S331345. eCollection 2021.
6
Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections.耐多药细菌感染的新兴治疗选择
Life (Basel). 2021 Jun 3;11(6):519. doi: 10.3390/life11060519.
7
Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria.革兰阳性菌和革兰阴性菌中的移动恶唑烷酮类耐药基因。
Clin Microbiol Rev. 2021 Jun 16;34(3):e0018820. doi: 10.1128/CMR.00188-20. Epub 2021 Jun 2.
8
Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe.新型恶唑烷酮类药物康替唑胺（MRX-I）针对来自美国和欧洲的革兰氏阳性临床分离株的活性和效价
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01195-20.

本文引用的文献

1
Phenotypic and genotypic characterization of linezolid-resistant Enterococcus faecium from the USA and Pakistan.美国和巴基斯坦屎肠球菌中利奈唑胺耐药表型和基因型特征。
J Antimicrob Chemother. 2019 Dec 1;74(12):3445-3452. doi: 10.1093/jac/dkz367.
2
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.血流感染的微生物学：来自 SENTRY 抗菌监测计划的 20 年趋势。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00355-19. Print 2019 Jul.
3
Analysis of a poxtA- and optrA-co-carrying conjugative multiresistance plasmid from Enterococcus faecalis.分析一株来自屎肠球菌的同时携带 poxtA 和 optrA 的可接合多重耐药质粒。
J Antimicrob Chemother. 2019 Jul 1;74(7):1771-1775. doi: 10.1093/jac/dkz109.
4
Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia.利奈唑胺与达托霉素治疗万古霉素耐药肠球菌血症的比较。
Ther Adv Infect Dis. 2019 Feb 13;6:2049936119828964. doi: 10.1177/2049936119828964. eCollection 2019 Jan-Dec.
5
Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.达托霉素治疗肠球菌菌血症的药效学分析：是时候改变折点了。
Clin Infect Dis. 2019 May 2;68(10):1650-1657. doi: 10.1093/cid/ciy749.
6
Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.达托霉素对小鼠大腿感染模型中粪肠球菌和屎肠球菌的药效学研究。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.00506-18. Print 2018 Oct.
7
Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program.在全球范围内肠球菌临床分离株中不断演变的恶唑烷酮类耐药机制：来自 SENTRY 抗菌药物监测计划的结果。
J Antimicrob Chemother. 2018 Sep 1;73(9):2314-2322. doi: 10.1093/jac/dky188.
8
ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.ZAAPS 项目 2016 年成果：使用来自 42 个国家的医疗中心的临床分离株对利奈唑胺进行的一项活性和谱分析。
J Antimicrob Chemother. 2018 Jul 1;73(7):1880-1887. doi: 10.1093/jac/dky099.
9
Characterization of poxtA, a novel phenicol-oxazolidinone-tetracycline resistance gene from an MRSA of clinical origin.从临床来源的耐甲氧西林金黄色葡萄球菌中发现的新型氯霉素-恶唑烷酮-四环素耐药基因 poxtA 的特征。
J Antimicrob Chemother. 2018 Jul 1;73(7):1763-1769. doi: 10.1093/jac/dky088.
10
In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis.体内达托霉素对实验性万古霉素耐药粪肠球菌心内膜炎的疗效。
J Antimicrob Chemother. 2018 Apr 1;73(4):981-986. doi: 10.1093/jac/dkx499.

评估 Tedizolid 对引起侵袭性感染的 spp. 的活性和耐药机制，包括美国和欧洲医疗中心需要优化达托霉素给药策略的分离株，时间为 2016 年至 2018 年。

Assessment of Tedizolid Activity and Resistance Mechanisms against a Collection of spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018.

机构信息

JMI Laboratories, North Liberty, Iowa, USA

JMI Laboratories, North Liberty, Iowa, USA.

出版信息

Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00175-20.

DOI:10.1128/AAC.00175-20
PMID:32015026
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7179311/
Abstract

High-level aminoglycoside resistance was noted in 30.0% of and 25.2% of isolates. Only 3.3% and 2.1% of isolates had elevated daptomycin MIC (≥2 mg/liter) and vancomycin resistance, respectively. In contrast, 37.4% to 40.3% of isolates exhibited these phenotypes. Tedizolid inhibited 98.9% to 100.0% of enterococci causing serious invasive infections, including resistant subsets. Oxazolidinone resistance was mainly driven by G2576T; however, and genes were also detected, including in the United States and Turkey.

摘要

高水平氨基糖苷类耐药在 30.0%的 和 25.2%的 分离株中被发现。只有 3.3%和 2.1%的 分离株的达托霉素 MIC（≥2 毫克/升）和万古霉素耐药分别升高。相比之下，37.4%至 40.3%的 分离株表现出这些表型。替加环素抑制导致严重侵袭性感染的肠球菌 98.9%至 100.0%，包括耐药亚群。唑烷酮类耐药主要由 G2576T 驱动；然而， 基因和 基因也被检测到，包括在美国和土耳其的 基因。